PT3354273T - Ligandos do recetor de melanocortina - Google Patents
Ligandos do recetor de melanocortinaInfo
- Publication number
- PT3354273T PT3354273T PT172028367T PT17202836T PT3354273T PT 3354273 T PT3354273 T PT 3354273T PT 172028367 T PT172028367 T PT 172028367T PT 17202836 T PT17202836 T PT 17202836T PT 3354273 T PT3354273 T PT 3354273T
- Authority
- PT
- Portugal
- Prior art keywords
- receptor ligands
- melanocortin receptor
- melanocortin
- ligands
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69777905P | 2005-07-08 | 2005-07-08 | |
US74885005P | 2005-12-09 | 2005-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3354273T true PT3354273T (pt) | 2021-06-28 |
Family
ID=37637790
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT172028367T PT3354273T (pt) | 2005-07-08 | 2006-07-10 | Ligandos do recetor de melanocortina |
PT10170694T PT2236151E (pt) | 2005-07-08 | 2006-07-10 | Ligandos do receptor de melanocortina |
PT101825669T PT2286825T (pt) | 2005-07-08 | 2006-07-10 | Ligandos do recetor de melanocortina |
PT121887848T PT2548568T (pt) | 2005-07-08 | 2006-07-10 | Ligandos do recetor de melanocortina |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT10170694T PT2236151E (pt) | 2005-07-08 | 2006-07-10 | Ligandos do receptor de melanocortina |
PT101825669T PT2286825T (pt) | 2005-07-08 | 2006-07-10 | Ligandos do recetor de melanocortina |
PT121887848T PT2548568T (pt) | 2005-07-08 | 2006-07-10 | Ligandos do recetor de melanocortina |
Country Status (21)
Country | Link |
---|---|
US (8) | US8039435B2 (pt) |
EP (6) | EP2286825B1 (pt) |
JP (4) | JP4734411B2 (pt) |
KR (2) | KR101232201B1 (pt) |
CN (4) | CN103755786B (pt) |
AU (2) | AU2006269261B2 (pt) |
CA (4) | CA3044795A1 (pt) |
DK (4) | DK3354273T3 (pt) |
ES (4) | ES2663916T3 (pt) |
FR (1) | FR21C1060I2 (pt) |
HK (2) | HK1149190A1 (pt) |
HU (4) | HUE037147T2 (pt) |
IL (3) | IL188545A (pt) |
NL (1) | NL301150I2 (pt) |
NZ (2) | NZ565217A (pt) |
PL (4) | PL2548568T3 (pt) |
PT (4) | PT3354273T (pt) |
RU (2) | RU2380372C2 (pt) |
SG (1) | SG163585A1 (pt) |
SI (1) | SI3354273T1 (pt) |
WO (1) | WO2007008704A2 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2548568T3 (pl) * | 2005-07-08 | 2018-06-29 | Ipsen Pharma | Ligandy receptora melanokortyny |
DE102007020152A1 (de) * | 2007-04-26 | 2008-10-30 | Charité - Universitätsmedizin Berlin | Mittel zur antiinfektiven Behandlung eines Patienten |
CA2689016C (en) | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
EP2167112A4 (en) * | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS |
CN101980717A (zh) * | 2007-11-05 | 2011-02-23 | 益普生制药股份有限公司 | 黑皮质素治疗胰岛素敏感的应用 |
KR20170102050A (ko) | 2008-05-27 | 2017-09-06 | 젠자임 코포레이션 | 알파-멜라노사이트 자극 호르몬의 펩티드 유사체 |
JP5628796B2 (ja) | 2008-06-09 | 2014-11-19 | パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. | 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド |
UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
WO2010144344A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
US20120135923A1 (en) * | 2009-08-05 | 2012-05-31 | Ipsen Pharma, S.A.S. | Use of Melanocortins to Treat Dyslipidemia |
WO2011026015A2 (en) * | 2009-08-31 | 2011-03-03 | Gruber Kenneth A | Stabilized melanocortin ligands |
US20120226018A1 (en) * | 2009-11-16 | 2012-09-06 | Ipsen Pharma, S.A.S. | Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 |
CN102665401A (zh) * | 2009-11-16 | 2012-09-12 | 益普生制药股份有限公司 | 黑皮质素受体配体的药物组合物 |
AU2010321739A1 (en) | 2009-11-23 | 2012-05-31 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific linear peptides |
JP5999702B2 (ja) | 2009-11-23 | 2016-09-28 | パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. | メラノコルチン−1受容体特異的環状ペプチド |
WO2012172433A2 (en) * | 2011-06-14 | 2012-12-20 | Ipsen Pharma S.A.S. | A sustained-release composition containing peptides as active ingredient |
PT2797615T (pt) | 2011-12-29 | 2019-07-11 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos |
EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
EP2944650A1 (en) | 2012-10-19 | 2015-11-18 | TXP Pharma GmbH | Alpha- and gamma- MSH analogues |
WO2014153221A2 (en) | 2013-03-14 | 2014-09-25 | Questcor Pharmaceuticals, Inc. | Acth for treatment of acute respiratory distress syndrome |
WO2014144260A1 (en) * | 2013-03-15 | 2014-09-18 | Rhythm Metabolic, Inc. | Peptide compositions |
KR102378943B1 (ko) * | 2013-03-15 | 2022-03-25 | 리듬 파마슈티컬즈, 인코포레이티드 | 약학적 조성물 |
BR112016024494B1 (pt) | 2014-04-22 | 2024-02-06 | Txp Pharma Gmbh | Análogo de peptídeo e seu uso |
JP6940853B2 (ja) * | 2015-09-30 | 2021-09-29 | リズム ファーマシューティカルズ, インコーポレイテッド | メラノコルチン4受容体経路関連障害を治療する方法 |
US11542302B2 (en) | 2015-10-15 | 2023-01-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulators of melanocortin receptors for the treatment of depression and anxiety |
WO2018074999A1 (en) * | 2016-10-17 | 2018-04-26 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Novel modulators of melanocortin receptors for the treatment of depression and anxiety |
WO2017066754A1 (en) * | 2015-10-15 | 2017-04-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for the treatment of depression and anxiety |
CN111032680A (zh) * | 2017-03-15 | 2020-04-17 | 诺和诺德股份有限公司 | 能够与黑皮质素4受体结合的双环化合物 |
AU2019249255A1 (en) | 2018-04-06 | 2020-11-05 | Alastair GARFIELD | Compositions for treating kidney disease |
US20210221867A1 (en) * | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
EP3820886A4 (en) * | 2018-05-23 | 2022-04-06 | Provincial Health Services Authority | RADIOLABELED MELANOCORTIN-1 RECEPTOR-SPECIFIC ALPHA MELANOCYT-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY |
US11396535B2 (en) | 2019-03-01 | 2022-07-26 | Provincial Health Services Authority | Cyclic peptide analogs of melanocortin and amanitin and methods of making such |
EP4216979A1 (en) * | 2020-09-24 | 2023-08-02 | Rhythm Pharmaceuticals, Inc. | Methods of treating melanocortin-4 receptor pathway-associated disorders |
WO2022251650A1 (en) * | 2021-05-27 | 2022-12-01 | The Regents Of The University Of Michigan | Mc3r agonist peptides |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US613874A (en) | 1898-11-08 | George e | ||
US1613874A (en) | 1922-03-29 | 1927-01-11 | Miner Inc W H | Friction draft gear |
US5652214A (en) | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
SE9700620D0 (sv) | 1997-02-21 | 1997-02-21 | Wapharm Ab | Cykliska peptider med selektivitet för MSH-receptor subtyper |
AU7464998A (en) | 1997-10-27 | 1999-05-17 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
US6127381A (en) * | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
CA2337495C (en) * | 1998-07-27 | 2008-03-18 | Iowa State University Research Foundation | Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals |
AU775289B2 (en) | 1998-08-21 | 2004-07-29 | Children's Medical Center Corporation | Use of melanin for inhibition of angiogenesis and macular degeneration |
US6716810B1 (en) | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
BR0009497A (pt) | 1999-03-29 | 2002-01-15 | Procter & Gamble | Ligantes de receptores de melanocortina |
US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
EP1241933B1 (en) | 1999-11-12 | 2008-10-01 | Merck & Co., Inc. | Melanocortin-3 receptor deficient cells, transgenic mice and methods of selecting compounds which regulate body weight |
US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
IL152781A0 (en) * | 2000-06-28 | 2003-06-24 | Pfizer Prod Inc | Melanocortin receptor ligands |
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
MXPA03002160A (es) | 2000-09-13 | 2004-05-04 | Eleanor Roosevelt Inst | Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes. |
US20030113263A1 (en) | 2001-02-13 | 2003-06-19 | Oregon Health And Sciences University, A Non-Profit Organization | Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia |
JP2005511475A (ja) | 2001-03-02 | 2005-04-28 | ブリストル−マイヤーズ スクイブ カンパニー | メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物 |
US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
AU2002322466B2 (en) * | 2001-07-11 | 2007-08-30 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
US7034004B2 (en) * | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
US20040128136A1 (en) * | 2002-09-20 | 2004-07-01 | Irani Pourang Polad | Internet voice browser |
WO2005000339A2 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(mc4) agonists and their uses |
US20060293223A1 (en) * | 2003-06-19 | 2006-12-28 | Eli Lilly And Company Patent Division | Uses of melanocortin-3 receptor (mc3r) agonist peptides |
US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
CA2530983C (en) * | 2003-08-20 | 2012-09-25 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
JP4767850B2 (ja) * | 2003-08-20 | 2011-09-07 | エミスフィアー テクノロジーズ インコーポレイテッド | グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤 |
US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
DE10355559A1 (de) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
EP1694348A4 (en) | 2003-12-10 | 2009-07-01 | Merck & Co Inc | VOLUNTARY INHIBITION OF CONSUMPTION OF ETHANOL USING MELANOCORTIN RECEPTOR 4 RECEPTOR AGONISTS |
US20070123453A1 (en) | 2004-03-29 | 2007-05-31 | Heiman Mark L | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion |
EP1812034A4 (en) | 2004-10-08 | 2009-07-29 | Clinuvel Pharmaceuticals Ltd | COMPOSITIONS AND METHODS OF INDUCING MELANOESEES IN ONE PERSON |
WO2006073772A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
WO2006073771A2 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
PL2548568T3 (pl) * | 2005-07-08 | 2018-06-29 | Ipsen Pharma | Ligandy receptora melanokortyny |
CA2620228C (en) | 2005-08-26 | 2014-12-09 | Action Pharma A/S | Therapeutically active .alpha.-msh analogues |
-
2006
- 2006-07-10 PL PL12188784T patent/PL2548568T3/pl unknown
- 2006-07-10 PT PT172028367T patent/PT3354273T/pt unknown
- 2006-07-10 JP JP2008520417A patent/JP4734411B2/ja active Active
- 2006-07-10 CA CA3044795A patent/CA3044795A1/en not_active Abandoned
- 2006-07-10 ES ES12188784.8T patent/ES2663916T3/es active Active
- 2006-07-10 CA CA3228910A patent/CA3228910A1/en active Pending
- 2006-07-10 CN CN201310495024.4A patent/CN103755786B/zh active Active
- 2006-07-10 PL PL10170694T patent/PL2236151T3/pl unknown
- 2006-07-10 EP EP10182566.9A patent/EP2286825B1/en active Active
- 2006-07-10 HU HUE12188784A patent/HUE037147T2/hu unknown
- 2006-07-10 EP EP21163411.8A patent/EP3925614A3/en active Pending
- 2006-07-10 DK DK17202836.7T patent/DK3354273T3/da active
- 2006-07-10 RU RU2008104803/04A patent/RU2380372C2/ru active
- 2006-07-10 PT PT10170694T patent/PT2236151E/pt unknown
- 2006-07-10 ES ES10170694T patent/ES2386862T3/es active Active
- 2006-07-10 EP EP10170694A patent/EP2236151B1/en active Active
- 2006-07-10 DK DK10182566.9T patent/DK2286825T3/en active
- 2006-07-10 US US11/988,533 patent/US8039435B2/en active Active
- 2006-07-10 PL PL17202836T patent/PL3354273T3/pl unknown
- 2006-07-10 CN CN201610168908.2A patent/CN105837661A/zh active Pending
- 2006-07-10 CN CN2006800324235A patent/CN101257916B/zh active Active
- 2006-07-10 HU HUE17202836A patent/HUE055154T2/hu unknown
- 2006-07-10 SI SI200632406T patent/SI3354273T1/sl unknown
- 2006-07-10 DK DK12188784.8T patent/DK2548568T3/en active
- 2006-07-10 NZ NZ565217A patent/NZ565217A/en unknown
- 2006-07-10 SG SG201004921-1A patent/SG163585A1/en unknown
- 2006-07-10 CA CA2614615A patent/CA2614615C/en active Active
- 2006-07-10 WO PCT/US2006/026586 patent/WO2007008704A2/en active Application Filing
- 2006-07-10 PT PT101825669T patent/PT2286825T/pt unknown
- 2006-07-10 EP EP17202836.7A patent/EP3354273B1/en active Active
- 2006-07-10 EP EP12188784.8A patent/EP2548568B1/en active Active
- 2006-07-10 CA CA2793119A patent/CA2793119C/en active Active
- 2006-07-10 CN CN200910174061A patent/CN101676298A/zh active Pending
- 2006-07-10 PL PL10182566T patent/PL2286825T3/pl unknown
- 2006-07-10 KR KR1020097022845A patent/KR101232201B1/ko active IP Right Grant
- 2006-07-10 RU RU2009131092/04A patent/RU2439079C2/ru active
- 2006-07-10 KR KR1020087002955A patent/KR100997177B1/ko active IP Right Grant
- 2006-07-10 AU AU2006269261A patent/AU2006269261B2/en active Active
- 2006-07-10 ES ES10182566.9T patent/ES2604328T3/es active Active
- 2006-07-10 PT PT121887848T patent/PT2548568T/pt unknown
- 2006-07-10 ES ES17202836T patent/ES2877349T3/es active Active
- 2006-07-10 NZ NZ580806A patent/NZ580806A/en not_active Application Discontinuation
- 2006-07-10 DK DK10170694.3T patent/DK2236151T3/da active
- 2006-07-10 EP EP06786665A patent/EP1915167A4/en not_active Withdrawn
- 2006-07-10 HU HUE10182566A patent/HUE031731T2/en unknown
-
2008
- 2008-01-02 IL IL188545A patent/IL188545A/en active IP Right Grant
- 2008-09-18 HK HK11103282.8A patent/HK1149190A1/xx unknown
-
2009
- 2009-10-25 IL IL201732A patent/IL201732A/en active IP Right Grant
- 2009-10-28 AU AU2009230799A patent/AU2009230799B2/en active Active
- 2009-11-19 JP JP2009263603A patent/JP5889513B2/ja active Active
-
2011
- 2011-03-29 US US13/074,565 patent/US9458195B2/en active Active
-
2013
- 2013-08-08 JP JP2013165312A patent/JP2013253090A/ja active Pending
-
2015
- 2015-07-14 JP JP2015140154A patent/JP5965520B2/ja active Active
-
2016
- 2016-06-22 IL IL246392A patent/IL246392A/en active IP Right Grant
- 2016-09-07 US US15/257,970 patent/US20160368962A1/en not_active Abandoned
-
2017
- 2017-05-05 US US15/587,426 patent/US9850280B2/en active Active
- 2017-12-04 US US15/830,038 patent/US20180105557A1/en not_active Abandoned
-
2018
- 2018-07-09 US US16/029,837 patent/US20180305406A1/en not_active Abandoned
-
2019
- 2019-01-28 HK HK19101447.6A patent/HK1258965A1/zh unknown
- 2019-12-04 US US16/702,661 patent/US20200095281A1/en not_active Abandoned
-
2021
- 2021-12-06 NL NL301150C patent/NL301150I2/nl unknown
- 2021-12-14 FR FR21C1060C patent/FR21C1060I2/fr active Active
- 2021-12-15 HU HUS2100054C patent/HUS2100054I1/hu unknown
-
2022
- 2022-01-10 US US17/572,115 patent/US20220127305A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100054I1 (hu) | Melanokortin receptor ligandumok | |
IL188544A0 (en) | Ligands of melanocortin receptors | |
EP1872421A4 (en) | MEANS FOR CONNECTING TERMINALS | |
GB0505941D0 (en) | Human-to-mobile interfaces | |
ZA200801743B (en) | Intermediate bracket | |
IL189265A0 (en) | Ferrocene-diphosphine ligands | |
EP1869271A4 (en) | SUPPORT | |
GB0624987D0 (en) | Novel aminoguanidines as melanocortin receptor ligands | |
GB0613762D0 (en) | Slabline structure | |
GB0516946D0 (en) | Receptor | |
GB0602684D0 (en) | Bracket | |
GB2418125B (en) | Saddle cover | |
GB0521122D0 (en) | Mat | |
GB0522484D0 (en) | Receptor | |
GB0510253D0 (en) | Receptor | |
GB0522077D0 (en) | Receptor | |
GB0522394D0 (en) | Receptor | |
GB0524953D0 (en) | Bracket | |
AU305163S (en) | Bracket | |
AU307179S (en) | Bracket | |
AU305162S (en) | Bracket | |
GB0514990D0 (en) | Mats | |
TWM291769U (en) | Ant-slip mat | |
GB0516849D0 (en) | Attachment means | |
GB0506820D0 (en) | Saddles |